BIOVITRUM AND SANTHERA SIGN AN EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT

Biovitrum AB, Sweden, and Swiss-based Santhera Pharmaceuticals AG have signed a license and collaboration agreement that grants Biovitrum the exclusive worldwide rights to Santhera's DPP-IV inhibitor program to select and develop compounds and sell future drugs for a range of metabolic diseases, including type 2 diabetes, obesity and metabolic syndrome. Under the terms of the agreement, Santhera will receive an upfront payment of Euro 4 million. In addition, this Biotech to Biotech deal allows both parties to receive a significant part of the commercial value of the overall project.

PrimeZone (http://www.primezone.com/newsroom/news.html?d=84099)